Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106305 | 0.93 | MAPT (0.54) | MAPTKDM4EGAAHTTMAPK1 | |
| SCHEMBL14931243 | 0.89 | GAA (0.52) | MAPTKDM4EGAAHTTMAPK1 | |
| SCHEMBL22502189 | 0.84 | MAPT (0.66) | MAPTKDM4EGAAHTTMAPK1 | |
| SCHEMBL5649965 | 0.84 | KDM4E (0.56) | MAPTKDM4EGAAHTTMAPK1 | |
| SCHEMBL2064577 | 0.82 | GAA (0.54) | MAPTKDM4EGAAHTTMAPK1 | |
| SCHEMBL4025990 | 0.82 | TUBB1 (0.55) | MAPTKDM4EGAAHTTMAPK1 | |
| SCHEMBL8250672 | 0.82 | MAPT (0.54) | MAPTKDM4EGAAHTTMAPK1 | |
| SCHEMBL5704645 | 0.82 | GAA (0.59) | MAPTKDM4EGAAHTTMAPK1 | |
| SCHEMBL14931191 | 0.81 | GAA (0.52) | MAPTKDM4EGAAHTTMAPK1 | |
| SCHEMBL22502366 | 0.81 | GAA (0.57) | MAPTKDM4EGAAHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2247294-A2 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | Basilea Pharmaceutica AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| CN-101331129-A | Dibenzonaphthyridine derivatives and methods of use thereof | WYETH CORP (US) | 2008-12-24 | — | — | CN | disclosed |
| EP-1963321-A2 | DIBENZONAPHTHYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7388016-B2 | Dibenzonaphthyridine derivatives and methods of use thereof | WYETH (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2007070319-A2 | DIBENZONAPHTHYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135429-A1 | Dibenzonaphthyridine derivatives and methods of use thereof | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | MAPT 4802/4885KDM4E 4433/4885GAA 2575/4885 |
| US-20070135429-A1 | Dibenzonaphthyridine derivatives and methods of use thereof | FANCD2, DDT, BRCA1 | MAPT 3976/4885KDM4E 3409/4885GAA 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.